home / stock / cbay / cbay news

CBAY News and Press, CymaBay Therapeutics Inc. From 11/04/22

Stock Information
Company Name: CymaBay Therapeutics Inc.
Stock Symbol: CBAY
Market: NASDAQ
Website: cymabay.com
Menu
CBAY CBAY Quote CBAY Short CBAY News CBAY Articles CBAY Message Board
Get CBAY Alerts

News, Short Squeeze, Breakout and More Instantly...
CBAY - CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced encouraging seladelpar data in pati...
CBAY - CymaBay Therapeutics to Present at Upcoming Investment Conferences

NEWARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Credit S...

CBAY - CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development

NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Charles McWherter as Pres...

CBAY - CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022

NEWARK, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that three abstracts related to its...
CBAY - CymaBay Therapeutics Hosting Virtual Analyst Day on September 22

Redefining Expectations for PBC Patients September 22, 2022 at 10:30 AM ET NEWARK, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic d...

CBAY - CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

NEWARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wa...

CBAY - CymaBay Therapeutics to Participate in B. Riley's Mini PBC Symposium on August 24, 2022

NEWARK, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in a mini sympo...
CBAY - CymaBay Therapeutics Inc. (CBAY) Q2 2022 Earnings Call Transcript

Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q2 2022 Earnings Call Transcript...

CBAY - Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2022 Results - Earnings Call Transcript

Cymabay Therapeutics, Inc. (CBAY) Q2 2022 Earnings Conference Call August 11, 2022, 16:30 ET Company Participants Paul Quinlan - General Counsel, Chief Compliance Officer & Corporate Secretary Sujal Shah - President, CEO & Director Charles McWherter - SVP...

CBAY - CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics press release ( NASDAQ: CBAY ): Q2 GAAP EPS of -$0.31 misses by $0.01 . Shares +5% . Held $170.8 million in cash, cash equivalents and investments as of June 30, 2022. We believe that cash and investments on hand are sufficient to fund Cyma...
Previous 10 Next 10